Human and animal studies demonstrate that xylooligosaccharides (XOS) are a highly efficacious prebiotic ingredient that delivers benefits at a minimum level of 1.4 g/day (d), which is much lower than levels required by fructooligosaccharides (FOS, 5 g/d) or galactooligosaccharides (GOS, 8 g/d). XOS promotes gastrointestinal regularity and relieves diarrhea and constipation at 0.7 g/d and 1.4 g/d, respectively. Xylooligosaccharides may also reduce blood cholesterol and may improve glycemic control, although more data from clinical trials are needed to confirm preliminary findings.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
DOUBLE
Enrollment
30
Maltodextrin 505mg/capsule 8 capsules/day (4 with breakfast and 4 with dinner meal)
8 capsules (512 mg/capsule) 4 with breakfast and 4 with dinner meal
8 capsules (520 mg/capsule) to be taken in the morning and in the evening
UCLA Center for Human Nutriiton
Los Angeles, California, United States
UCLA Center for Human Nutrition, David Geffen School of Medicine
Los Angeles, California, United States
The Effects of Xyloologosarcharide (XOS) on colonic bifidobacteria counts in healthy volunteers.
After a 2 weeks of run-in, 30 healthy volunteers were randomly assigned to take 1.4 grams/day of XOS, or 2.8 grams/day or placebo for 8 weeks. The bifidobarteria counts was assessed at screening, baseline, 4, 8 weeks on supplementation of XOS and after 2 week cessation of XOS.
Time frame: 10 weeks
Tolerance of XOS by healthy volunteers
The tolerance of XOS was assessed by questionnaires, adverse event logs with comparison with placebo control group
Time frame: 10 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.